Telix was created to deliver on the promise of nuclear medicine.
Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic (‘theranostic’) assets using Molecularly Targeted Radiation (MTR). Nuclear medicine is finally coming of age, with commercial critical mass building and commitment to late-stage product development. Our goal is to harness this momentum for the benefit of patients, with MTR potentially offering better-informed treatment decisions and truly personalised therapy.
Telix’s product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.
Telix’s research pipeline aims to address significant unmet medical need in prostate, kidney, brain (glioblastoma), and hematologic cancers as well as a range of immunologic and rare diseases. We are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio.
Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. In 2020, Telix acquired a production facility in Seneffe, Belgium, with one of the broadest private sector medical isotope licences in Europe. This delivers significant operational flexibility, and ensures the ability to meet commercial production requirements in Europe.
Through collaboration, we multiply our contribution to the delivery of our goals and to improving the lives of those living with cancer.
We implement new ideas & technologies to meet our goals and the unmet medical needs of people living with cancer.
We are trustworthy and reliable, we practice and encourage open communication, we are responsible for our actions.
We are passionate about delivering on our goals and improving the lives of people living with cancer.
We respect our colleagues, our collaborators, our mentors, and the collective contribution of experts in our field.